Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs
T Mizuno, M Kato, T Tsukui, M Igase - Veterinary Immunology and Immunopathology, 2024
Immunomodulatory antibody drugs that modulate the function of immune checkpoint
molecules, such as programmed death receptor-1 (PD-1) and programmed cell
death ligand 1 (PD-L1), have been established as new cancer treatments in human
medicine. In recent years, there have also been reports on antibodies that inhibit
immune checkpoint molecules in dogs, and clinical trials using such antibodies for
canine cancer have been gradually increasing in number. Because inhibitory …
molecules, such as programmed death receptor-1 (PD-1) and programmed cell
death ligand 1 (PD-L1), have been established as new cancer treatments in human
medicine. In recent years, there have also been reports on antibodies that inhibit
immune checkpoint molecules in dogs, and clinical trials using such antibodies for
canine cancer have been gradually increasing in number. Because inhibitory …
| • | 引用: A canine chimeric monoclonal antibody targeting PD-L1 and its …   |